IP Library Granted Patent US 8,093,242
Granted Patent B2
US 8,093,242 · App. 13/056,775 · Granted Jan 10, 2012

Crystalline forms of a pyridine derivative

Assignee: GlaxoSmithKline LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,093,242
App. No.
13/056,775
Granted
Jan 10, 2012
Kind
B2
Abstract

The invention relates to 4-methylbenzenesulfonate salt of the compound of formula (I) in a crystalline form or a solvate thereof, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.

Claims (10)

1. 4-methylbenzenesulfonate salt of the compound of formula (I)

or a hydrate thereof in a crystalline form.

2. 4-methylbenzenesulfonate salt of the compound of formula (I) in a crystalline form as claimed in claim 1 , wherein the crystalline form is anhydrous.

3. 4-methylbenzenesulfonate salt of the compound of formula (I) in a crystalline form as claimed in claim 1 , wherein the crystalline form is hydrate.

4. 4-methylbenzenesulfonate salt of the compound of formula (I) in a crystalline form as claimed in claim 1 , wherein the crystalline form is anhydrous crystalline Form 1 characterized by substantially the same X-ray powder diffraction (XRPD) pattern as in FIG. 1 .

5. 4-methylbenzenesulfonate salt of the compound of formula (I) in a crystalline form as claimed in claim 1 , wherein the crystalline form is anhydrous crystalline Form 2 characterized by substantially the same X-ray powder diffraction (XRPD) pattern as in FIG. 3 .

6. 4-methylbenzenesulfonate salt of the compound of formula (I) in a crystalline form as claimed in claim 1 , wherein the crystalline form is hydrate 1 characterized by substantially the same X-ray powder diffraction (XRPD) pattern as in FIG. 5 .

7. A pharmaceutical composition comprising 4-methylbenzenesulfonate salt of the compound of formula (I) or a hydrate thereof in a crystalline form according to claim 1 .

8. A pharmaceutical composition according to claim 7 further comprising one or more pharmaceutically acceptable carriers or diluents.

9. A method for the treatment of psychotic disorders, depression, mood disorders, anxiety, sleep disorders and alcohol dependence comprising administering to the mammal, an effective amount of 4-methylbenzenesulfonate salt of the compound of formula (I) or a hydrate thereof in a crystalline form according to claim 1 .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2020
From: NERRE THERAPEUTICS LIMITED
To: KANDY THERAPEUTICS LIMITED
Reel/Frame 054687/0378 →
CHANGE OF ADDRESS Recorded Dec 9, 2020
From: NERRE THERAPEUTICS LIMITED
To: NERRE THERAPEUTICS LIMITED
Reel/Frame 054663/0915 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2013
From: GLAXOSMITHKLINE LLC
To: NERRE THERAPEUTICS LIMITED
Reel/Frame 029794/0242 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2011
From: CLAPHAM, DAVID; ANDERTON, CLARE LOUISE; LAWRENCE, RONNIE MAXWELL
To: GLAXOSMITHKLINE LLC
Reel/Frame 025736/0356 →
Priority Claims (1)
GB 0814340.6 · Aug 5, 2008 · national
Continuity (1)
Related Publication 20110136798A1 · Jun 9, 2011